Drug intelligence / Profile preview

diaboherb

Development stage: Unknown
Lead developer: SBL Homeopathy
Administration: Oral

Overview

Diaboherb is a polyherbal health supplement developed by SBL for the treatment of Type 2 Diabetes Mellitus. It is designed to manage hyperglycemia and alleviate common diabetic symptoms such as polyuria (frequent urination), polydipsia (excessive thirst), polyphagia (excessive hunger), and myalgia. In a prospective, randomized, double-blind, placebo-controlled proof-of-concept clinical trial involving 150 patients, Diaboherb demonstrated significant efficacy in reducing fasting blood sugar (FBS), postprandial blood sugar (PPBS), and glycated hemoglobin (HbA1c) levels. The product was reported to be safe with no adverse events observed during the study period.

Brand names: Diaboherb
Other names: Diaboherb 1Diaboherb1Diaboherb-1Diaboherb 2Diaboherb2Diaboherb-2

Beyond the preview

Go deeper on diaboherb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diaboherb.

Explore the full profile